Latest Innovation News

NH3 Clean Energy updates investors on the WAH2 clean ammonia project, highlighting strong market potential, strategic partnerships, and robust project economics as it moves toward a Final Investment Decision.

PainChek Limited has achieved a landmark FDA De Novo classification for its PainChek Adult App, positioning it as the first regulated medical device for pain assessment in the US aged care sector and opening a $100 million annual market opportunity.

Anatara Lifesciences has completed the first tranche of its two-part share placement, issuing over 33 million ordinary shares to professional investors. This move marks a significant step in the company’s capital raising efforts amid ongoing product development.

OpenLearning Limited has raised $2.6 million through a well-supported equity placement to accelerate its global growth and AI-driven product development, targeting new markets like the Philippines and Brazil.

Locksley Resources has produced a high-grade antimony concentrate exceeding market standards from its Desert Antimony Mine in California, marking a significant step toward a fully domestic US antimony supply chain.

Alliance Aviation Services announces founder Scott McMillan will step down as Joint Managing Director at the November AGM, with Stewart Tully set to become sole Managing Director, concluding a year-long succession plan.

Neurotech International has secured a key FDA designation for its lead drug NTI164, advancing its potential to treat Rett syndrome with regulatory and financial benefits.

Pro Medicus Limited’s European arm, Visage Imaging, has landed a significant five-year, A$10 million contract to supply next-generation imaging technology to University Hospital Heidelberg and the German Cancer Research Institute, marking a strategic expansion in Europe.

Ovanti Limited has secured $8 million through a strategic share placement to accelerate its US Buy Now, Pay Later expansion, highlighted by a new three-year NASCAR sponsorship deal.

Immuron Limited has taken a significant step forward by submitting an Investigational New Drug application to the FDA for IMM-529, targeting Clostridioides difficile infection. The company aims to start Phase 2 trials in early 2026, addressing a critical unmet need in infectious disease treatment.

Redox Limited reported a 9.4% increase in sales revenue for FY25 despite challenging global conditions, while declaring a robust dividend payout that exceeds its policy. The company’s strategic focus on specialty chemicals, operational expansion, and ESG commitments positions it well for continued growth.

Airtasker has landed a £2.5 million media investment from Channel 4’s venture arm to accelerate growth in the UK, building on a strong marketplace performance and deepening a strategic media partnership.